Cargando…

Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model

BACKGROUND: Primary cytoreductive surgery followed by adjuvant chemotherapy is the standard treatment for advanced epithelial ovarian cancer. The average interval between surgery and chemotherapy initiation is approximately 4-weeks at most centers; however, since surgery may accelerate residual tumo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yooyoung, Kollara, Alexandra, May, Taymaa, Brown, Theodore J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032528/ https://www.ncbi.nlm.nih.gov/pubmed/29973223 http://dx.doi.org/10.1186/s13048-018-0428-6

Ejemplares similares

A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin
por: Clark, Mitchell, et al.
Publicado: (2021)

The impact of interval between primary cytoreductive surgery with bowel resection and initiation of adjuvant chemotherapy on survival of women with advanced ovarian cancer: a multicenter cohort study
por: Lee, Yoo-Young, et al.
Publicado: (2022)

Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2015)

VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation
por: Shathasivam, Premalatha, et al.
Publicado: (2017)

Development of a syngeneic mouse model of epithelial ovarian cancer
por: Quinn, Bridget A, et al.
Publicado: (2010)

Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity
por: Kollara, Alexandra, et al.
Publicado: (2012)

Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model
por: Nounamo, Bernice, et al.
Publicado: (2017)

A Syngeneic Mouse Model of Epithelial Ovarian Cancer Port Site Metastases
por: Wilkinson-Ryan, Ivy, et al.
Publicado: (2018)

Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer
por: Cook, David P., et al.
Publicado: (2023)

SDF-1α Mediates Wound-Promoted Tumor Growth in a Syngeneic Orthotopic Mouse Model of Breast Cancer
por: Stuelten, Christina H., et al.
Publicado: (2013)

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
por: Marchocki, Zibi, et al.
Publicado: (2022)

Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model
por: Wilson, Andrew J, et al.
Publicado: (2013)

Dynamic Distribution of Nuclear Coactivator 4 during Mitosis: Association with Mitotic Apparatus and Midbodies
por: Kollara, Alexandra, et al.
Publicado: (2011)

Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model
por: Ocak, Meltem, et al.
Publicado: (2014)

Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model
por: Lin, Kai-Ti, et al.
Publicado: (2017)

Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer
por: Alvero, Ayesha B., et al.
Publicado: (2020)

Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model
por: Ranoa, Diana Rose E, et al.
Publicado: (2023)

Enhanced Growth of Syngeneic Moloney Sarcoma with Decreased Immunity in the Regressors
por: Mayer, A. M. S., et al.
Publicado: (1977)

Protocol to assess the antitumor efficacy of an immunotherapeutic peptide in syngeneic orthotopic glioma mouse models
por: Chen, Apeng, et al.
Publicado: (2023)

Ventricular Zone Expressed PH Domain Containing 1 (VEPH1): an adaptor protein capable of modulating multiple signaling transduction pathways during normal and pathological development
por: Brown, Theodore J., et al.
Publicado: (2019)

THE CYTOTOXIC EFFECT OF MOUSE MACROPHAGES ON SYNGENEIC AND ALLOGENEIC ERYTHROCYTES
por: Melsom, H., et al.
Publicado: (1973)

Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells
por: Rabelo-Fernández, Robert J., et al.
Publicado: (2022)

Glucocorticoid-Induced Reversal of Interleukin-1β-Stimulated Inflammatory Gene Expression in Human Oviductal Cells
por: Backman, Stéphanie, et al.
Publicado: (2014)

Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
por: Zhong, Wenyan, et al.
Publicado: (2020)

Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer
por: Zhang, P, et al.
Publicado: (2014)

Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response
por: Zeng, Zexian, et al.
Publicado: (2022)

Molecular Profiling and Clinical Outcome of High-Grade Serous Ovarian Cancer Presenting with Low- versus High-Volume Ascites
por: Feigenberg, Tomer, et al.
Publicado: (2014)

Radiation Responses of Subrenally Transplanted Syngeneic and Allogeneic Mouse Fibrosarcomas
por: Sato, Setsu, et al.
Publicado: (1988)

Single-Cell Landscape of Mouse Islet Allograft and Syngeneic Graft
por: Chen, Pengfei, et al.
Publicado: (2022)

DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model
por: Wilson, Amy L., et al.
Publicado: (2021)

Searching for Promoters to Drive Stable and Long-Term Transgene Expression in Fibroblasts for Syngeneic Mouse Tumor Models
por: Antonova, Dina V., et al.
Publicado: (2020)

TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response
por: Zeng, Zexian, et al.
Publicado: (2021)

Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer
por: Russell, Shonagh, et al.
Publicado: (2022)

Modeling Immune Checkpoint Inhibitor Efficacy in Syngeneic Mouse Tumors in an Ex Vivo Immuno-Oncology Dynamic Environment
por: Doty, Daniel T., et al.
Publicado: (2020)

Spontaneous Physical Activity in Obese Condition Favours Antitumour Immunity Leading to Decreased Tumour Growth in a Syngeneic Mouse Model of Carcinogenesis
por: Le Guennec, Delphine, et al.
Publicado: (2021)

An HNSCC syngeneic mouse model for tumor immunology research and preclinical evaluation
por: Fu, You, et al.
Publicado: (2020)

Promotion of fibrosarcoma cell growth by products of syngeneic host macrophages.
por: Currie, G. A.
Publicado: (1981)

Comparison of cisplatin-induced anti-tumor response in CT26 syngeneic tumors of three BALB/c substrains
por: Gong, Jeong Eun, et al.
Publicado: (2021)

Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
por: Bieg, Dominik, et al.
Publicado: (2018)

Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer
por: Greenaway, James B., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nfbng5lsk4lg7rt0l82irui7vs